On behalf of the National Cannabis Industry Association (NCIA), and in response to the U.S.
Food and Drug Administration (FDA) request for comments on Scientific Data and Information
About Products Containing Cannabis or Cannabis-Derived Compounds, published in the April 3,
2019 edition of the Federal Register, we hereby submit public comments.
In addition to our specific expertise, and on behalf of NCIA members and the cannabis and
cannabidiol (CBD)/hemp industries at large, we have formed a coalition of CBD/hemp
entrepreneurs, scientists, medical professionals, and food and drug lawyers to provide public
comment to the FDA and to answer specific questions posed by the FDA, to provide general
context about the industry, and to highlight relevant work that we have previously done on
packaging, labeling, and lab testing that could inform FDA rulemaking.